The data that we presented to FDA from 107 people in our pilot studies, including Tony, showed that 23 percent of the people that received therapy without active MDMA no longer had PTSD at the end of treatment.
Los datos que presentamos a la FDA. de 107 personas de nuestros estudios piloto, incluido Tony, mostró que el 23 % de las personas que recibieron terapia sin MDMA activa ya no tenía TEPT al final del tratamiento.